Expand NTLA Menu
NTLA MENU

NTLA Latest Press Releases

-- August 6, 2026 --

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates Globe Newswire 7:00 AM

-- July 30, 2026 --

Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates Globe Newswire 8:00 AM

-- July 6, 2026 --

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- June 13, 2026 --

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Globe Newswire 7:30 AM

-- June 5, 2026 --

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- June 1, 2026 --

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026 Globe Newswire 7:30 AM

-- May 11, 2026 --

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates Globe Newswire 7:30 AM

-- May 5, 2026 --

Intellia Therapeutics to Participate in Upcoming Investor Conferences Globe Newswire 7:30 AM

-- May 1, 2026 --

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- April 29, 2026 --

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock Globe Newswire 7:00 AM

-- April 27, 2026 --

Intellia Announces Proposed Public Offering of Common Stock Globe Newswire 4:01 PM
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing Globe Newswire 7:00 AM
Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema Globe Newswire 7:00 AM

-- April 24, 2026 --

Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026 Globe Newswire 4:05 PM

-- April 8, 2026 --

The Credibility Filter Wall Street Uses to Sort Biotech Winners Globe Newswire 9:15 AM

-- April 3, 2026 --

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM
Market Data Delayed 15 Minutes